Webinar: Protein Quantitation for Characterization of Potential Cancer Therapeutics in Early Discovery and Mechanism of Action Insights in Translational Studies

Protein quantitation is important to gain insights about disease mechanisms and find biomarkers. In this presentation from the American Association for Cancer Research® (AACR) Annual Meeting 2025, we highlight how Simple Western™ Technology is advancing cancer research by providing size resolution and precise protein quantitation.

Key Topics Covered

Fabian Meili, Principal Scientist at Novartis discusses how Simple Western was utilized to identify and characterize a selective and potent BRM degrader targeting the less conserved bromo-domain of an ATPase in the BAF complex that mediates oncogenic transcription factor networks.

Dr. Maya Ridinger, R&D Director at Cardiff Oncology discusses how Simple Western was utilized to gain mechanistic insights into the antiangiogenic effect of onvansertib, supporting its potential and mechanisms of action in combination with standard-of-care in KRAS-mutant mCRC.

Speakers 

Fabian Meili
Principal Scientist, Novartis

Maya Ridinger, PhD
Director, R&D, Cardiff Oncology

Brendan McIntyre
Senior Field Applications Scientist, Bio-Techne